Some of the "guts" would be -
- 13 patients now recruited, they believe the full 20 by mid September
- US FDA concession that half can be treated in non US centres
- $8m cash on hand against anticipated $6.7m (CR still expected in 2018)
- Possibility of cash generating patients before CR if CE Mark granted
- Likely to be awarded CE Mark approval by end of 2017
OSL Price at posting:
8.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)